Overview
Jana Grieb has been advising pharmaceutical and medical technology companies on all aspects of health law for over 20 years. She accompanies pharmaceuticals, medical devices, and in vitro diagnostics throughout their entire life cycle – from research and development to market access, advertising and distribution. One main area of her work is providing legal and strategic advice on market entry and reimbursement paths in the European Union, with a particular focus on the EU regulations on medical devices and in vitro diagnostics and the law governing statutory health insurance in Germany. In this context, Jana also advises on research and distribution collaborations.
Besides her regulatory focus, Jana provides comprehensive advice on compliance issues in the healthcare market, including aspects of competition and medical advertising law, cooperation with professionals under anti-corruption and association law requirements, as well as background advice on commercial criminal law. She supports her clients in the establishment and further development of their compliance management.
Finally, Jana advises with broad experience on the borderline of health markets to neighboring product markets, mainly food, cosmetics, wellness and electronic products.
Jana is a regular speaker and author of numerous publications on pharmaceutical and medical device law.
Results
Jana advised:
- lifespin GmbH with regard to a research cooperation with Biobank Graz and the clinical oncology department of the medical university of Graz
- AUCTUS Capital Partners AG with regard to the sale of the PharmaLex-Group
- Myonex, Inc. in the acquisition of the clinical trials department of Hubertus Apotheke
- Merck KgaA in negotiations for a cooperation agreement with neuroloop GmbH, an early phase start-up of B. Braun group
- Medline Industries, Inc. in the sale of the majority share in the company (strategic healthcare regulatory advice)
- Apax in the sale of the clinical lab chain Unilabs to Maersk
Recognitions
- The Best Lawyers in Germany, Pharmaceuticals Law, 2021 to 2024
- Legal 500 Deutschland/EMEA 2019-2022: Recommended for Healthcare & Life Sciences-Germany
- Chambers Europe 2015-2022 Germany: Recommended for Healthcare & Life Sciences-Germany
- Chambers Europe 2023, Band 4 in Germany: Life Sciences
Community
- German Lawyers’ Association, Working Group for Medical Law
- German Federal Association for the Pharmaceutical Industry
